RS110504A - Pharmaceutical use of nitric oxide, heme oxygenase-1 and products of heme degradation - Google Patents
Pharmaceutical use of nitric oxide, heme oxygenase-1 and products of heme degradationInfo
- Publication number
- RS110504A RS110504A YUP-1105/04A YUP110504A RS110504A RS 110504 A RS110504 A RS 110504A YU P110504 A YUP110504 A YU P110504A RS 110504 A RS110504 A RS 110504A
- Authority
- RS
- Serbia
- Prior art keywords
- heme
- nitric oxide
- products
- pharmaceutical use
- degradation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/04—Amoebicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Inorganic Chemistry (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
Abstract
Predmetni pronalazak se odnosi na lečenje poremećaja, korišćenjem azot monoksida (NO), hem oksigenaze-1 (HO-1) i proizvoda hema, kao što su ugljen monoksid (CO), biliverdin, bilirubin i gvoždje.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39045702P | 2002-06-21 | 2002-06-21 | |
PCT/US2003/019609 WO2004000368A1 (en) | 2002-06-21 | 2003-06-20 | Pharmaceutical use of nitric oxide, heme oxygenase-1 and products of heme degradation |
Publications (1)
Publication Number | Publication Date |
---|---|
RS110504A true RS110504A (en) | 2007-02-05 |
Family
ID=30000561
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
YUP-1105/04A RS110504A (en) | 2002-06-21 | 2003-06-20 | Pharmaceutical use of nitric oxide, heme oxygenase-1 and products of heme degradation |
Country Status (13)
Country | Link |
---|---|
US (2) | US20040131703A1 (sr) |
EP (1) | EP1515753A4 (sr) |
JP (1) | JP2005533812A (sr) |
CN (1) | CN1674942A (sr) |
AU (1) | AU2003279236B8 (sr) |
CA (1) | CA2490392A1 (sr) |
EA (1) | EA200500062A1 (sr) |
HR (1) | HRP20041204A2 (sr) |
MX (1) | MXPA04012863A (sr) |
NO (1) | NO20050011L (sr) |
PL (1) | PL375161A1 (sr) |
RS (1) | RS110504A (sr) |
WO (1) | WO2004000368A1 (sr) |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8128963B2 (en) * | 1996-09-27 | 2012-03-06 | The Trustees Of Columbia University In The City Of New York | Methods for treating ischemic disorders using carbon monoxide |
US20070086954A1 (en) * | 1998-11-23 | 2007-04-19 | Miller Christopher C | Method and apparatus for treatment of respiratory infections by nitric oxide inhalation |
CA2254645A1 (en) * | 1998-11-23 | 2000-05-23 | Pulmonox Medical Corporation | Method and apparatus for treatment of respiratory infections by nitric oxide inhalation |
US7678390B2 (en) | 1999-04-01 | 2010-03-16 | Yale University | Carbon monoxide as a biomarker and therapeutic agent |
US7516742B2 (en) * | 1999-11-24 | 2009-04-14 | Cardinal Health 207, Inc. | Method and apparatus for delivery of inhaled nitric oxide to spontaneous-breathing and mechanically-ventilated patients with intermittent dosing |
US6432077B1 (en) * | 2000-12-26 | 2002-08-13 | Sensormedics Corporation | Device and method for treatment of surface infections with nitric oxide |
US7122018B2 (en) * | 2000-12-26 | 2006-10-17 | Sensormedics Corporation | Device and method for treatment of wounds with nitric oxide |
ATE413883T1 (de) * | 2001-06-21 | 2008-11-15 | Beth Israel Hospital | Kohlenmonoxid verbessert die ergebnisse bei gewebe- und organtransplantationen und unterdrückt apoptose |
WO2003066067A2 (en) * | 2002-02-04 | 2003-08-14 | Alfama - Investigaçao E Desenvolvimento De Produtos Farmaceuticos Lda. | Use of co-releasing compounds for the manufacture of a medicament for the treatment of inflammatory diseases |
MXPA04010243A (es) | 2002-04-15 | 2005-07-05 | Univ Pittsburgh | Metodos para tratar ileo. |
US8097585B2 (en) | 2002-04-15 | 2012-01-17 | Beth Israel Deaconess Medical Center, Inc. | Methods of treating inflammation by administration of heme oxygenase-1 and products of heme degradation |
EP1499328B1 (en) | 2002-04-15 | 2015-09-16 | University of Pittsburgh - Of the Commonwealth System of Higher Education | Methods of treating necrotizing enterocolitis |
EP1505990B1 (en) * | 2002-05-17 | 2011-08-24 | Yale University | Methods of treating hepatitis |
MXPA04012167A (es) * | 2002-06-05 | 2005-09-21 | Univ Yale | Metodos para tratar angiogenesis, crecimeinto tumoral y metastasis. |
US7531133B2 (en) * | 2002-09-10 | 2009-05-12 | Pulmonox Technologies Corporation | Use of nitric oxide gas in an extracorporeal circuitry to treat blood plasma |
DE10249552A1 (de) | 2002-10-23 | 2004-05-13 | Vifor (International) Ag | Wasserlösliche Eisen-Kohlenhydrat-Komplexe, deren Herstellung und diese enthaltende Arzneimittel |
AU2003283982A1 (en) * | 2002-11-07 | 2004-06-03 | University Of Pittsburgh Of The Commonwealth System Of High Education | Treatment for hemorrhagic shock |
US20070117769A1 (en) * | 2003-09-29 | 2007-05-24 | Maines Mahin D | Methods of modulating cell cycle and cell signaling pathways using biliverdin reductase |
WO2005077005A2 (en) * | 2004-02-04 | 2005-08-25 | The General Hospital Corporation | Enhancing the effectiveness of an inhaled therapeutic gas |
EP1755715A4 (en) * | 2004-05-11 | 2010-03-24 | Sensormedics Corp | INTERMITTENT DETERMINATION OF GASEOUS NITRIC OXIDE |
US8518457B2 (en) * | 2004-05-11 | 2013-08-27 | Pulmonox Technologies Corporation | Use of inhaled gaseous nitric oxide as a mucolytic agent or expectorant |
US20070154570A1 (en) * | 2004-09-29 | 2007-07-05 | Miller Christopher C | Use of nitric oxide in the treatment and disinfection of biofilms |
MX2007013196A (es) * | 2005-04-20 | 2008-01-18 | Hutchinson Fred Cancer Res | Metodos, composiciones y articulos de fabricacion para mejorar la supervivencia de celulas, tejidos, organos y organismos. |
US20090214618A1 (en) | 2005-05-27 | 2009-08-27 | Schoenfisch Mark H | Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications |
MX2008004284A (es) * | 2005-09-30 | 2008-10-23 | Ovation Pharmaceuticals Inc | Metodo para tratar pancreatitis. |
WO2007057763A2 (en) * | 2005-11-18 | 2007-05-24 | Pulmonox Technologies Corporation | Nitric oxide as an anti-viral agent, vaccine and vaccine adjuvant |
WO2007073005A1 (ja) * | 2005-12-22 | 2007-06-28 | Keio University | メチル基転移反応調節物質 |
WO2007073006A1 (ja) * | 2005-12-22 | 2007-06-28 | Keio University | 細胞保護性を有するアミノ酸の増加誘導剤及び増加方法 |
CA2635894C (en) | 2006-01-06 | 2017-09-12 | Luitpold Pharmaceuticals, Inc. | Methods and compositions for administration of iron |
US8790715B2 (en) | 2006-02-16 | 2014-07-29 | Ino Therapeutics Llc | Method and apparatus for generating nitric oxide for medical use |
WO2007103427A2 (en) * | 2006-03-06 | 2007-09-13 | Wang Xiang H | Medical use of bilirubin and its structural analogues |
JP5020525B2 (ja) * | 2006-03-30 | 2012-09-05 | 財団法人生産開発科学研究所 | 配位子置換型輸液製剤 |
GB0613362D0 (en) * | 2006-07-05 | 2006-08-16 | Hemocorm Ltd | Therapeutic delivery of carbon monoxide |
WO2008008513A2 (en) * | 2006-07-13 | 2008-01-17 | Beth Israel Deaconess Medical Center Inc. | Combination treatments |
WO2008048514A2 (en) * | 2006-10-13 | 2008-04-24 | Nitric Biotherapeutics, Inc. | Topical nitric oxide as a treatment of autoimmune diseases |
US8079998B2 (en) * | 2006-10-20 | 2011-12-20 | Pulmonox Technologies Corporation | Methods and devices for the delivery of therapeutic gases including nitric oxide |
US20080193566A1 (en) * | 2007-02-09 | 2008-08-14 | Miller Christopher C | Use of high dose concentrations of gaseous nitric oxide |
US20100196516A1 (en) * | 2007-04-24 | 2010-08-05 | ALFAMA-Investigacao e Desenvolvimento de produtos Farmaceuticos, Lda | Treatment of infections by carbon monoxide |
JP2010530001A (ja) * | 2007-06-15 | 2010-09-02 | イカリア, インコーポレイテッド | 硫化物単独または一酸化窒素との組み合わせを含む組成物およびその使用 |
EP2182961B1 (en) * | 2007-07-24 | 2012-05-02 | Alfama - Investigaçao e Desenvolvimento de Productos Farmaceuticos LDA. | Prevention of gastric ulcery by carbon monoxide |
EP2445508B1 (en) | 2009-06-22 | 2018-11-14 | VERO Biotech LLC | Nitric oxide therapies |
CA2771308C (en) | 2009-08-21 | 2020-01-21 | Novan, Inc. | Topical gels comprising nitric oxide releasing polysiloxane macromolecules |
CA2771389C (en) | 2009-08-21 | 2019-04-09 | Novan, Inc. | Wound dressings, methods of using the same and methods of forming the same |
EP2519297A4 (en) | 2009-12-31 | 2013-08-21 | Univ Ohio | SYSTEMS AND METHODS FOR PROMOTING HEALING |
CN102762101B (zh) * | 2010-02-18 | 2014-09-17 | 高点制药有限责任公司 | 取代的稠合咪唑衍生物、药物组合物及其使用方法 |
WO2012050874A2 (en) * | 2010-09-28 | 2012-04-19 | Soares Miguel P | Targeting heme for the treatment of immune mediated inflammatory diseases |
US8591876B2 (en) | 2010-12-15 | 2013-11-26 | Novan, Inc. | Methods of decreasing sebum production in the skin |
WO2012118829A2 (en) | 2011-02-28 | 2012-09-07 | Novan, Inc. | Tertiary s-nitrosothiol-modified nitricoxide-releasing xerogels and methods of using the same |
BR112013023740A2 (pt) | 2011-03-16 | 2016-08-02 | Dynasil Biomedical Corp | métodos e materiais para prolongamento da armazenagem útil de preparações de glóbulo vermelho e preparações de plaqueta |
US9163044B2 (en) | 2011-04-19 | 2015-10-20 | Alfama, Inc. | Carbon monoxide releasing molecules and uses thereof |
JP6134710B2 (ja) | 2011-07-21 | 2017-05-24 | アルファーマ インコーポレイテッドAlfama,Inc. | 一酸化ルテニウム放出分子およびその使用 |
US9987302B2 (en) | 2011-08-09 | 2018-06-05 | Beth Israel Deaconess Medical Center, Inc. | Methods of treating DNA damage |
US9763899B2 (en) | 2012-08-30 | 2017-09-19 | The Board Of Trustees Of The Leland Stanford Junior University | Iron chelators and use thereof for reducing transplant failure during rejection episodes |
TW201618795A (zh) * | 2014-04-15 | 2016-06-01 | 波泰里斯股份有限公司 | 用以改良器官功能及延長器官移植物壽命之系統及方法 |
US10314860B2 (en) | 2015-05-21 | 2019-06-11 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Compositions and methods for treating and preventing venom related poisoning |
CN105727379A (zh) * | 2016-02-25 | 2016-07-06 | 顾宇春 | 血红素加氧酶药物洗脱支架 |
CN105748485A (zh) * | 2016-03-28 | 2016-07-13 | 暨南大学 | 亚铁原卟啉在制备预防和治疗急性co中毒的药物的应用 |
KR101962518B1 (ko) * | 2016-09-13 | 2019-03-26 | 울산대학교 산학협력단 | 일산화탄소 또는 일산화탄소 공급체를 유효성분으로 함유하는 아세트아미노펜 유도 간 독성 예방 또는 치료용 조성물 |
US20180169142A1 (en) * | 2016-12-19 | 2018-06-21 | Nobilis Therapeutics, Inc. | Methods, means and compositions for improving outcomes of surgical interventions and inflammatory sequel |
WO2019090075A1 (en) * | 2017-11-02 | 2019-05-09 | Ait Therapeutics, Inc. | Inhalation of nitric oxide |
AU2018360849A1 (en) * | 2017-11-02 | 2020-05-28 | Beyond Air, Inc. | Inhalation of nitric oxide |
CN110038014A (zh) * | 2019-04-18 | 2019-07-23 | 上海康孕企业管理合伙企业(有限合伙) | 血红素在改善夜间尿频的药物、食品及保健食品中的应用 |
US20230140515A1 (en) * | 2021-11-03 | 2023-05-04 | Baxter International Inc. | Nitric oxide donors for use in surgical recovery |
KR20240015199A (ko) * | 2022-07-26 | 2024-02-05 | 한양대학교 산학협력단 | 간/지방조직 이중 표적 복합 나노 약물 전달체 |
Family Cites Families (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4053590A (en) * | 1975-02-27 | 1977-10-11 | Alza Corporation | Compositions of matter comprising macromolecular hemoglobin |
US4264739A (en) * | 1979-01-05 | 1981-04-28 | Merck & Co., Inc. | Sparger for cell culture system |
US5240912A (en) * | 1983-05-09 | 1993-08-31 | Todaro George J | Transforming growth factor (TGF) peptides |
US4979939A (en) * | 1984-05-14 | 1990-12-25 | Surgical Systems & Instruments, Inc. | Atherectomy system with a guide wire |
US5084380A (en) * | 1985-01-29 | 1992-01-28 | Applied Biotechnology | Monoclonal antibodies reactive with activated and oncogenic ras p21 proteins |
US5449665A (en) * | 1985-09-24 | 1995-09-12 | Item Development Aktiebolag | Continuous intravenous infusion of adenosine to human patients undergoing percutaneous transluminal angioplasty |
DE3739650C1 (de) * | 1987-11-23 | 1989-05-24 | Immuno Ag | Fermenter zum Zuechten von Zellkulturen |
US5180366A (en) * | 1990-10-10 | 1993-01-19 | Woods W T | Apparatus and method for angioplasty and for preventing re-stenosis |
US5792325A (en) * | 1990-11-15 | 1998-08-11 | Richardson, Jr.; William H. | Electric arc material processing system |
WO1992010228A1 (en) * | 1990-12-05 | 1992-06-25 | The General Hospital Corporation | Devices for treating pulmonary vasoconstriction and asthma |
US5570683A (en) * | 1990-12-05 | 1996-11-05 | The General Hospital Corporation | Methods and devices for treating pulmonary vasoconstriction and asthma |
US5293875A (en) * | 1992-06-16 | 1994-03-15 | Natus Medical Incorporated | In-vivo measurement of end-tidal carbon monoxide concentration apparatus and methods |
US5731526A (en) * | 1992-09-23 | 1998-03-24 | Kindrick; Dudley R. | System for displaying the amount of fluid dispensed from a hand-held sprayer |
DK0693924T4 (da) * | 1993-02-22 | 2008-08-04 | Abraxis Bioscience Inc | Fremgangsmåde til (in vivo) levering af biologiske materialer og sammensætninger, der er egnede dertil |
US5985307A (en) * | 1993-04-14 | 1999-11-16 | Emory University | Device and method for non-occlusive localized drug delivery |
US5523092A (en) * | 1993-04-14 | 1996-06-04 | Emory University | Device for local drug delivery and methods for using the same |
US5763431A (en) * | 1993-08-20 | 1998-06-09 | Jackson; Meyer B. | Method for regulating neuropeptide hormone secretion |
US5588962A (en) * | 1994-03-29 | 1996-12-31 | Boston Scientific Corporation | Drug treatment of diseased sites deep within the body |
DE4421433C1 (de) * | 1994-06-18 | 1995-06-08 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System mit Wirkstoffen, die Kohlenmonoxid-Quellen darstellen, Verfahren zu seiner Herstellung und seine Verwendung |
US5476764A (en) * | 1994-09-16 | 1995-12-19 | The Regents Of The University Of California | Method using CO for extending the useful shelf-life of refrigerated red blood cells |
US6066333A (en) * | 1994-09-22 | 2000-05-23 | William Harvey Research Limited | Pharmaceutical control of inflammation |
US5664563A (en) * | 1994-12-09 | 1997-09-09 | Cardiopulmonary Corporation | Pneumatic system |
US5914316A (en) * | 1994-12-16 | 1999-06-22 | Washington University | Method of inhibiting intimal hyperplasia |
US6063407A (en) * | 1995-02-16 | 2000-05-16 | The General Hospital Corporation | Treatment of vascular thrombosis and restenosis with inhaled nitric oxide |
US5712293A (en) * | 1995-06-07 | 1998-01-27 | Sepracor, Inc. | Methods for treating gastro-esophageal reflux disease and other disorders associated with the digestive tract using optically pure (-) norcisapride |
FR2735382B1 (fr) * | 1995-06-15 | 1997-07-25 | Air Liquide | Installation de production de monoxyde de carbone incorporant une unite de separation cryogenique |
DE19535781C2 (de) * | 1995-09-26 | 1999-11-11 | Fraunhofer Ges Forschung | Vorrichtung zur aktiven Strömungsunterstützung von Körperflüssigkeiten |
DK0914103T3 (da) * | 1996-04-05 | 2006-10-23 | Gen Hospital Corp | Behandling af hæmoglobinopati |
US6069132A (en) * | 1996-08-14 | 2000-05-30 | Revanker; Ganapathi R. | Phosphazole compounds |
WO1998007447A1 (en) * | 1996-08-23 | 1998-02-26 | Algos Pharmaceutical Corporation | Anticonvulsant containing composition for treating neuropathic pain |
US8128963B2 (en) * | 1996-09-27 | 2012-03-06 | The Trustees Of Columbia University In The City Of New York | Methods for treating ischemic disorders using carbon monoxide |
US6316403B1 (en) * | 1996-09-27 | 2001-11-13 | The Trustees Of Columbia University In The City Of New York | Methods for treating an ischemic disorder and improving stroke outcome |
US6436365B2 (en) * | 1997-09-23 | 2002-08-20 | Schering Aktiengesellschaft | Process for therapeutic treatment of proliferative diseases |
US6656452B1 (en) * | 1997-10-21 | 2003-12-02 | The General Hospital Corporation | Use of inhaled NO as anti-inflammatory agent |
US6251418B1 (en) * | 1997-12-18 | 2001-06-26 | C.R. Bard, Inc. | Systems and methods for local delivery of an agent |
US6450989B2 (en) * | 1998-04-27 | 2002-09-17 | Artemis Medical, Inc. | Dilating and support apparatus with disease inhibitors and methods for use |
US6203991B1 (en) * | 1998-08-21 | 2001-03-20 | The Regents Of The University Of Michigan | Inhibition of smooth muscle cell migration by heme oxygenase I |
US7678390B2 (en) * | 1999-04-01 | 2010-03-16 | Yale University | Carbon monoxide as a biomarker and therapeutic agent |
US20050250688A1 (en) * | 1999-04-01 | 2005-11-10 | The Trustees Of Columbia University In The City Of New York | Methods for treating an ischemic disorder and improving stroke outcome |
US6142067A (en) * | 1999-04-06 | 2000-11-07 | Roth; Eldon | Apparatus for treating ammoniated meats |
US20040038192A1 (en) * | 1999-04-14 | 2004-02-26 | Breonics, Inc. | System for exsanguinous metabolic support of an organ or tissue |
US7632803B2 (en) * | 1999-10-01 | 2009-12-15 | Dmi Life Sciences, Inc. | Metal-binding compounds and uses therefor |
SE9903985D0 (sv) * | 1999-11-03 | 1999-11-03 | Aga Ab | Use of nitric oxide |
US6811965B2 (en) * | 2000-03-08 | 2004-11-02 | Yoram Vodovotz | Kidney perfusion solution containing nitric oxide donor, inhibitor of NOS2, glutathione, gluconate and methods of use |
US6508784B1 (en) * | 2000-05-19 | 2003-01-21 | Yan-Ho Shu | Balloon catheter having adjustable centering capabilities and methods thereof |
US6601580B1 (en) * | 2000-06-28 | 2003-08-05 | The General Hospital Corporation | Enhancing therapeutic effectiveness of nitric oxide inhalation |
FR2812197B1 (fr) * | 2000-07-27 | 2003-01-03 | Air Liquide Sante Int | Utilisation de co dans le traitement de l'inflammation des voies aeriennes superieures ou des bronches |
FR2816212A1 (fr) * | 2000-11-03 | 2002-05-10 | Air Liquide Sante Int | Utilisation de monoxyde de carbone (co) dans le traitement des inflammations du systeme cardiovasculaire |
WO2002080859A2 (en) * | 2001-03-20 | 2002-10-17 | Glaxo Group Limited | Inhalation drug combinations |
MXPA03008820A (es) * | 2001-03-30 | 2004-07-30 | Sangstat Medical Corp | Compuestos generadores de monoxido de carbono, para el tratamiento de desordenes vasculares, inflamatorios e inmunologicos. |
GB0111872D0 (en) * | 2001-05-15 | 2001-07-04 | Northwick Park Inst For Medica | Therapeutic agents and methods |
EP1395241B9 (en) * | 2001-05-25 | 2005-06-15 | Medtronic, Inc. | Implantable medical device with controllable gaseous agent release system |
ATE413883T1 (de) * | 2001-06-21 | 2008-11-15 | Beth Israel Hospital | Kohlenmonoxid verbessert die ergebnisse bei gewebe- und organtransplantationen und unterdrückt apoptose |
CA2475963A1 (en) * | 2002-02-13 | 2003-09-04 | Beth Israel Deaconess Medical Center, Inc. | Methods of treating vascular disease |
JP2005537223A (ja) * | 2002-04-05 | 2005-12-08 | ニトロメッド,インク. | 酸化窒素供与体、組成物および使用法 |
EP1499328B1 (en) * | 2002-04-15 | 2015-09-16 | University of Pittsburgh - Of the Commonwealth System of Higher Education | Methods of treating necrotizing enterocolitis |
US8097585B2 (en) * | 2002-04-15 | 2012-01-17 | Beth Israel Deaconess Medical Center, Inc. | Methods of treating inflammation by administration of heme oxygenase-1 and products of heme degradation |
MXPA04010243A (es) * | 2002-04-15 | 2005-07-05 | Univ Pittsburgh | Metodos para tratar ileo. |
EP1505990B1 (en) * | 2002-05-17 | 2011-08-24 | Yale University | Methods of treating hepatitis |
MXPA04012167A (es) * | 2002-06-05 | 2005-09-21 | Univ Yale | Metodos para tratar angiogenesis, crecimeinto tumoral y metastasis. |
AU2003283982A1 (en) * | 2002-11-07 | 2004-06-03 | University Of Pittsburgh Of The Commonwealth System Of High Education | Treatment for hemorrhagic shock |
AU2003293529A1 (en) * | 2002-12-16 | 2004-07-29 | Nitromed, Inc. | Nitrosated and nitrosylated rapamycin compounds, compositions and methods of use |
WO2005077005A2 (en) * | 2004-02-04 | 2005-08-25 | The General Hospital Corporation | Enhancing the effectiveness of an inhaled therapeutic gas |
-
2003
- 2003-06-20 CN CNA038197367A patent/CN1674942A/zh active Pending
- 2003-06-20 MX MXPA04012863A patent/MXPA04012863A/es unknown
- 2003-06-20 PL PL03375161A patent/PL375161A1/xx unknown
- 2003-06-20 RS YUP-1105/04A patent/RS110504A/sr unknown
- 2003-06-20 EP EP03742119A patent/EP1515753A4/en not_active Withdrawn
- 2003-06-20 WO PCT/US2003/019609 patent/WO2004000368A1/en active Application Filing
- 2003-06-20 EA EA200500062A patent/EA200500062A1/ru unknown
- 2003-06-20 CA CA002490392A patent/CA2490392A1/en not_active Abandoned
- 2003-06-20 AU AU2003279236A patent/AU2003279236B8/en not_active Withdrawn - After Issue
- 2003-06-20 US US10/600,182 patent/US20040131703A1/en not_active Abandoned
- 2003-06-20 JP JP2004516066A patent/JP2005533812A/ja not_active Withdrawn
-
2004
- 2004-12-20 HR HR20041204A patent/HRP20041204A2/xx not_active Application Discontinuation
-
2005
- 2005-01-03 NO NO20050011A patent/NO20050011L/no not_active Application Discontinuation
-
2007
- 2007-10-31 US US11/931,645 patent/US20080171021A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2003279236B2 (en) | 2009-01-22 |
HRP20041204A2 (en) | 2005-06-30 |
EP1515753A4 (en) | 2009-07-15 |
US20080171021A1 (en) | 2008-07-17 |
JP2005533812A (ja) | 2005-11-10 |
EP1515753A1 (en) | 2005-03-23 |
CN1674942A (zh) | 2005-09-28 |
EA200500062A1 (ru) | 2005-06-30 |
AU2003279236B8 (en) | 2009-02-19 |
NO20050011L (no) | 2005-03-18 |
PL375161A1 (en) | 2005-11-28 |
MXPA04012863A (es) | 2005-03-31 |
AU2003279236A1 (en) | 2004-01-06 |
US20040131703A1 (en) | 2004-07-08 |
WO2004000368A1 (en) | 2003-12-31 |
CA2490392A1 (en) | 2003-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RS110504A (en) | Pharmaceutical use of nitric oxide, heme oxygenase-1 and products of heme degradation | |
EP1401479A4 (en) | DETECTION AND THERAPY OF VULNERABLE PLATES USING PHOTODYNAMIC COMPOUNDS | |
TW200608979A (en) | Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | |
SG164368A1 (en) | Treatment of cancer | |
NO20052348L (no) | Behandling av hemoragisk sjokk | |
YU20050003A (sh) | Postupak i uređaj za davanje co | |
RS91004A (en) | Methods of treating ileus | |
PH12013500123A1 (en) | Hemiasterlin derivatives and uses thereof | |
EA200401525A1 (ru) | Способы лечения гепатита (варианты ) | |
UA86570C2 (ru) | Способ лечения некротизирующего энтероколита | |
WO2003088748A8 (en) | Use of heme oxygenase-1 and products of heme degradation | |
MY141528A (en) | Anilinopyrazole derivatives useful for the treatment of diabetes | |
EP1392328A4 (en) | ANTICANCER THERAPY | |
WO2002094189A3 (en) | Compositions and methods for treating or preventing convulsions or seizures | |
HK1081862A1 (en) | Synergistic combination comprising roflumilast and (r,r)-formoterol | |
HK1079116A1 (en) | Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and radiotherapy | |
AU4779599A (en) | Methods of inhibiting (helicobacter pylori) | |
WO2008008513A3 (en) | Combination treatments | |
EP1417968A3 (en) | Antitumour compositions containing propolis and resveratrol | |
BG106259A (en) | Means for the treatment of burns |